1、 Drug Name Trade Name Indictions Manufacturer Timechlorambucil Leukeran Chronic Lymphocytic Leukemia- palliative therapy GlaxoSmithKline meclorethamine, nitrogen mustard Mustargen Merck Mar 15 1949 leucovorin Wellcovorin, Leucovorin Leucovorin calcium is indicated fro use in combination with 5-fluor
2、ouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Immunex Corporation Jun 20 1952 mercaptopurine, 6-MP Purinethol GlaxoSmithKline Sep 11 1953 methotrexate Methotrexate Lederle Laboratories Dec 07 1953 busulfan oral Myleran Chronic Myelogenous Leukem
3、ia- palliative therapy GlaxoSmithKline Jun 26 1954 chlorambucil Leukeran GlaxoSmithKline Mar 18 1957 thiotepa Thioplex Immunex Corporation Mar 09 1959 methotrexate Methotrexate Lederle Laboratories Aug 10 1959 nandrolone phenpropionate Durabolin-50 Organon Oct 30 1959 cyclophosphamide Cytoxan, Neosa
4、r Bristol-Myers Squibb Nov 16 1959 cyclophosphamide Cytoxan Injection Bristol-Myers Squibb Nov 16 1959 DROMOSTANOLONE PROPIONATE DROMOSTANOLONE Eli Lilly Oct 26 1961 fluorouracil, 5-FU Adrucil prolong survival in combination with leucovorin ICN Puerto Rico Apr 25 1962 Uracil Mustard Uracil Mustard C
5、apsules Roberts Labs Sep 13 1962 vincristine Oncovin Eli Lilly Jul 10 1963 vincristine Oncovin Eli Lilly Jul 10 1963 vincristine Oncovin Eli Lilly Jul 10 1963 vincristine Oncovin Eli Lilly Jul 10 1963 vincristine Oncovin Eli Lilly Jul 10 1963 vincristine Oncovin Eli Lilly Jul 10 1963 vincristine Onc
6、ovin Eli Lilly Jul 10 1963 melphalan, L-PAM Alkeran GlaxoSmithKline Jan 17 1964 dactinomycin, actinomycin D Cosmegen Merck Feb 04 1964 DROMOSTANOLONE PROPIONATE MASTERONE INJECTION SYNTEX Oct 08 1964 quinacrine Atabrine Abbott Labs Dec 07 1964 dactinomycin, actinomycin D Cosmegan Merck Dec 10 1964 v
7、inblastine Velban Eli Lilly Nov 05 1965 thioguanine, 6-TG Thioguanine GlaxoSmithKline Jan 18 1966 pipobroman Vercyte Abbott Labs Jul 01 1966 hydroxyurea Hydrea Bristol-Myers Squibb Dec 07 1967 testolactone Teslac Bristol-Myers Squibb Jun 03 1969 cytarabine Cytosar-U Pharmacia & Upjohn Company Jun 17
8、 1969 procarbazine Matulane Sigma Tau Pharms Jul 22 1969 plicamycin, mithramycin Mithracin Pfizer Labs May 05 1970 testolactone Teslac Bristol-Myers Squibb May 27 1970 mitotane Lysodren Bristol-Myers Squibb Jul 08 1970 floxuridine (intraarterial) FUDR Roche Dec 18 1970 megestrol acetate Megace Brist
9、ol-Myers Squibb Aug 18 1971 methotrexate Methotrexate Lederle Laboratories Nov 01 1971 methotrexate Methotrexate Lederle Laboratories Nov 01 1971 calusterone Methosarb Pharmacia & Upjohn Company Feb 20 1973 bleomycin Blenoxane Bristol-Myers Squibb Jul 31 1973 mitomycin C Mutamycin Bristol-Myers Squi
10、bb May 28 1974 doxorubicin Adriamycin, Rubex Pharmacia & Upjohn Company Aug 07 1974 dacarbazine DTIC-Dome Bayer May 27 1975 lomustine, CCNU CeeBU Bristol-Myers Squibb Aug 04 1976 carmustine BCNU, BiCNU Bristol-Myers Squibb Mar 07 1977 tamoxifen Nolvadex AstraZeneca Pharmaceuticals Dec 30 1977 cispla
11、tin Platinol Metastatic testicular-in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors whoc have already received appropriate surgical and/or radiotherapeutic procedures. An established combination therapy consists of Platinol,
12、 Blenoxane and Velbam. Bristol-Myers Squibb Dec 19 1978 cisplatin Platinol Metastatic ovarian tumors - in established combination therapy with other approved chemotherapeutic agents: Ovarian-in established Bristol-Myers Squibb Dec 19 1978 combination therapy with other approved chemotherapeutic agen
13、ts in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Platinol and Adriamycin. Platinol, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors r
14、efractory to standard chemotherapy who have not previously received Platinol therapy. estramustine Emcyt palliation of prostate cancer Pharmacia & Upjohn Company Dec 24 1981 streptozocin Zanosar Antineoplastic agent. Pharmacia & Upjohn Company May 07 1982 etoposide, VP-16 Vepesid Refractory testicul
15、ar tumors-in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic and radiotherapeutic therapy. Bristol-Myers Squibb Nov 10 1983 tamoxifen Nolvadex As a single agent to delay bre
16、ast cancer recurrence following total mastectomy and axillary dissection in postmenopausal women with breast cancer (T1-3, N1, M0) AstraZeneca Pharmaceuticals Dec 03 1986 etoposide, VP-16 VePesid In combination with other approved chemotherapeutic agents as first line treatment in patients with smal
17、l cell lung cancer. Bristol-Myers Squibb Dec 30 1986 etoposide, VP-16 Vepesid In combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. Bristol-Myers Squibb Dec 30 1986 leucovorin Leucovorin Immunex Corporation Jan 30 1987 leucovorin
18、Leucovorin Immunex Corporation Jan 30 1987 daunorubicin, daunomycin Cerubidine In combination with approved anticancer drugs for induction of Wyeth Ayerst Mar 11 1987 remission in adult ALL. cyclophosphamide Cytoxan Injection Bristol-Myers Squibb Apr 29 1987 cyclophosphamide Cytoxan Tablet Bristol-M
19、yers Squibb Apr 29 1987 doxorubicin Adriamycin PFS Injectionintravenous injection Antibiotic, antitumor agent. Pharmacia & Upjohn Company Dec 23 1987 mitoxantrone Novantrone For use with other approved drugs in the initial therapy for acute nonlymphocytic leukemia (ANLL) in adults. Lederle Laborator
20、ies Dec 23 1987 methotrexate Methotrexate osteosarcoma Lederle Laboratories Apr 07 1988 leucovorin Leucovorin Immunex Corporation Aug 31 1988 methotrexate Methotrexate Lederle Laboratories Oct 31 1988 ifosfamide IFEX Third line chemotherapy of germ cell testicular cancer when used in combination wit
21、h certain other approved antineoplastic agents. Bristol-Myers Squibb Dec 30 1988 mesna Mesnex Prevention of ifosfamide-induced hemorrhagic cystitis Asta Medica Dec 30 1988 carboplatin Paraplatin Palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including pat
22、ients who have been previously treated with cisplatin. Bristol-Myers Squibb Mar 03 1989 tamoxifen Nolvadex For use in premenopausal women with metastatic breast cancer as an alternative to oophorectomy or ovarian irradiation AstraZeneca Pharmaceuticals Mar 16 1989 pegademase Adagen (Pegademase Bovin
23、e) Enzyme replacement therapy for patients with severe combined immunodeficiency asa result of adenosine deaminase deficiency. Enzon Mar 21 1990 levamisole Ergamisol Adjuvant treatment in combination with 5-fluorouracil after surgical resection in patients with Dukes Stage C colon cancer. Janssen Re
24、search Foundation Jun 18 1990 tamoxifen Nolvadex For use in women with axillary node-negative breast cancer adjuvant AstraZeneca Jun 21 1990 therapy. Pharmaceuticals thiotepa Thioplex Lederle Laboratories Aug 15 1990 idarubicin Idamycin For use in combination with other approved antileukemic drugs f
25、or the treatment of acute myeloid leukemia (AML) in adults. Adria Laboratories Sep 27 1990 altretamine Hexalen Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination. US Bioscie
26、nce Dec 26 1990 Filgrastim Neupogen Amgen, Inc Feb 20 1991 fludarabine Fludara Palliative treatment of patients with B-cell lymphocytic leukemia (CLL) who have not responded or have progressed during treatment with at least one standard alkylating agent containing regimen. Berlex Laboratories Inc. A
27、pr 18 1991 carboplatin Paraplatin Initial chemotherapy of advanced ovarian carcinoma in combination with other approved chemotherapeutic agents. Bristol-Myers Squibb Jul 05 1991 pentostatin Nipent Single agent treatment for adult patients with alpha interferon refractory hairy cell leukemia. Parke-D
28、avis Pharmaceutical Co. Oct 11 1991 leucovorin Leucovorin In combination with fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Lederle Laboratories Dec 12 1991 Aldesleukin Proleukin Chiron Corp May 05 1992 teniposide, VM-26 Vumon In combinatio
29、n with other approved anticancer agents for induction therapy in patients with refractory childhood acute lymphoblastic leukemia (all). Bristol-Myers Squibb Jul 14 1992 melphalan, L-PAM Alkeran Systemic administration for palliative treatment of patients with multiple myeloma for whom oral therapy i
30、s not appropriate. GlaxoSmithKline Nov 18 1992 paclitaxel Taxol Treatment of patients with metastatic carcinoma of the ovary after Bristol-Myers Squibb Dec 29 1992 failure of first-line or subsequent chemotherapy. cladribine Leustatin, 2-CdA Treatment of active hairy cell leukemia. R.W. Johnson Phar
31、maceutical Research Institute Feb 26 1993 tamoxifen Nolvadex Metastatic breast cancer in men. AstraZeneca Pharmaceuticals Apr 01 1993 cisplatin Platinol as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radioth
32、erapy. Bristol-Myers Squibb Apr 22 1993 pentostatin Nipent Single-agent treatment for untreated hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. (Supplement for front -line therapy.) Parke-Davis
33、Pharmaceutical Co. Sep 29 1993 Pegaspargase Oncaspar Enzon, Inc Feb 01 1994 tamoxifen Nolvadex Equal bioavailability of a 20 mg Nolvadex tablet taken once a day to a 10 mg Nolvadex tablet taken twice a day. AstraZeneca Pharmaceuticals Mar 21 1994 paclitaxel Taxol Treatment of breast cancer after fai
34、lure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Bristol-Myers Squibb Apr 13 1994 paclitaxel Taxol New dosing regimen for patients who have failed initia
35、l or subsequent chemotherapy for metastatic carcinoma of the ovary Bristol-Myers Squibb Jun 22 1994 thiotepa Thioplex Immunex Corporation Dec 22 1994 vinorelbine Navelbine Single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced no
36、n- GlaxoSmithKline Dec 23 1994 small cell lung cancer (NSCLC). dexrazoxane Zinecard Accel. Approv. (clinical benefit subsequently established) Prevention of cardiomyopathy associated with doxorubicin administration Pharmacia & Upjohn Company May 26 1995 doxorubicin liposomal Doxil Accel. Approv. (cl
37、inical benefit not established) Treatment of AIDS-related Kaposis sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. Sequus Pharmaceuticals, Inc. Nov 17 1995 tretinoin, ATRA Vesanoid Induction of remission in pati
38、ents with acute promyelocytic leukemia (APL) who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens. Roche Nov 22 1995 amifostine Ethyol To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced
39、 ovarian cancer US Bioscience Dec 08 1995 goserelin acetate Zoladex Implant Palliative treatment of advanced breast cancer in pre- and perimenopausal women. AstraZeneca Pharmaceuticals Dec 18 1995 goserelin acetate Zoladex AstraZeneca Pharmaceuticals Dec 18 1995 anastrozole Arimidex Treatment of adv
40、anced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. AstraZeneca Pharmaceuticals Dec 27 1995 porfimer sodium Photofrin For use in photodynamic therapy (PDT) for palliation of patients with completely obstructing esophageal cancer, or patients with partial
41、ly obstructing esophageal cancer who cannot be satisfactorily treated with ND-YAG laser therapy. QLT Phototherapeutics Inc. Dec 27 1995 bleomycin Blenoxane Sclerosing agent for the treatment of malignant pleural effusion (MPE) and prevention of recurrent pleural effusions. Bristol-Myers Squibb Feb 2
42、0 1996 amifostine Ethyol Accel. Approv. (clinical benefit not established) Reduction of platinum US Bioscience Mar 15 1996 toxicity in non-small cell lung cancer daunorubicin liposomal DanuoXome First line cytotoxic therapy for advanced, HIV related Kaposis sarcoma. Nexstar, Inc. Apr 08 1996 docetax
43、el Taxotere Accel. Approv. (clinical benefit subsequently established) Treatment of patients with locally advanced or metastatic breast cancer who have progressed during anthracycline-based therapy or have relapsed during anthracycline-based adjuvant therapy. Aventis Pharmaceutical May 14 1996 gemci
44、tabine Gemzar Treatment of patients with locally advanced (nonresectable stage II or III) or metastatic (stage IV) adenocarcinoma of the pancreas. Indicated for first-line treatment and for patients previously treated with a 5-fluorouracil-containing regimen. Eli Lilly May 15 1996 allopurinol Zylopr
45、im Patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy. GlaxoSmithKline May 17 1996 etoposide phosphate Etopophos Management of refractory testicular tumors,
46、in combination with other approved chemotherapeutic agents. Bristol-Myers Squibb May 17 1996 etoposide phosphate Etopophos Management of small cell lung cancer, first-line, in combination with other approved chemotherapeutic agents. Bristol-Myers Squibb May 17 1996 topotecan Hycamtin Treatment of pa
47、tients with metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. GlaxoSmithKline May 28 1996 irinotecan Camptosar Accel. Approv. (clinical benefit subsequently established) Treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recu
48、rred or progressed following 5-FU-based therapy. Pharmacia & Upjohn Company Jun 14 1996 Nofetumomab Verluma Boehringer Ingelheim Pharma KG (formerly Dr. Aug 20 1996 Karl Thomae GmbH) carmustine with Polifeprosan 20 Implant Gliadel Wafer For use in addition to surgery to prolong survival in patients
49、with recurrent glioblastoma multiforme who qualify for surgery. Guilford Pharmaceuticals Inc. Sep 23 1996 Elliotts B Solution Elliotts B Solution Diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma. Orphan Medical, Inc Sep 27 1996 Interferon alfa-2a Roferon-A Hoffmann-La Roche Inc Nov 01 1996 Sargramostim Prokine Immunex Corp Nov 07 1996 mitoxantrone Novantrone For use in combination
